Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Raised to Strong-Buy at DZ Bank

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) was upgraded by investment analysts at DZ Bank from a “hold” rating to a “strong-buy” rating in a research report issued on Tuesday,Zacks.com reports.

BAYRY has been the topic of a number of other reports. Zacks Research upgraded shares of Bayer Aktiengesellschaft from a “strong sell” rating to a “hold” rating in a report on Friday, May 8th. UBS Group upgraded shares of Bayer Aktiengesellschaft from a “neutral” rating to a “buy” rating in a report on Monday, March 16th. Three investment analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Buy”.

Bayer Aktiengesellschaft Stock Up 2.6%

OTCMKTS BAYRY opened at $11.34 on Tuesday. The company has a debt-to-equity ratio of 1.22, a current ratio of 1.01 and a quick ratio of 0.63. The company’s 50 day simple moving average is $11.29 and its 200 day simple moving average is $11.07. Bayer Aktiengesellschaft has a 12 month low of $6.69 and a 12 month high of $14.85. The company has a market capitalization of $44.57 billion, a P/E ratio of -17.72, a PEG ratio of 3.52 and a beta of 0.62.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last released its earnings results on Tuesday, May 12th. The company reported $0.79 EPS for the quarter, topping analysts’ consensus estimates of $0.64 by $0.15. Bayer Aktiengesellschaft had a negative net margin of 4.75% and a positive return on equity of 17.74%. The business had revenue of $15.73 billion for the quarter, compared to the consensus estimate of $15.77 billion. Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.200-1.346 EPS. Equities research analysts expect that Bayer Aktiengesellschaft will post 1.25 earnings per share for the current fiscal year.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.